Tempus AI (NASDAQ:TEM) Director David Epstein Sells 250 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 250 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.40, for a total transaction of $12,350.00. Following the transaction, the director directly owned 31,464 shares of the company’s stock, valued at $1,554,321.60. This represents a 0.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $47.51 on Thursday. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The company has a 50 day simple moving average of $48.83 and a two-hundred day simple moving average of $57.67. The company has a market capitalization of $8.53 billion, a price-to-earnings ratio of -27.62 and a beta of 3.62. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. During the same quarter last year, the firm earned ($0.24) earnings per share. The business’s revenue for the quarter was up 36.1% on a year-over-year basis. Analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TEM. Robert W. Baird began coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 target price for the company. Guggenheim decreased their target price on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a report on Monday. Mizuho started coverage on shares of Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $80.00 price target on shares of Tempus AI in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $68.64.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares in the last quarter. ARK Investment Management LLC lifted its holdings in shares of Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after purchasing an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new position in shares of Tempus AI during the fourth quarter valued at $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.